<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01784536</url>
  </required_header>
  <id_info>
    <org_study_id>MDCO-ORI-12-03</org_study_id>
    <nct_id>NCT01784536</nct_id>
  </id_info>
  <brief_title>Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers</brief_title>
  <acronym>DDI</acronym>
  <official_title>Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, N-Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults Using the Cooperstown 5 + 1 Cocktail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Medicines Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Medicines Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of oritavancin on the in vivo activities
      of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, NAT 2, and XO using a Cooperstown 5 + 1 cocktail
      in an open label, single arm manner.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the phenotyping measures of each probe drug in the absence and presence of oritavancin</measure>
    <time_frame>Day 1 through Day 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of probe drug administration and prolonged infusion of oritavancin as assessed by AEs/SAEs, clinical safety laboratory results, vital sign measurements, 12 lead ECG results, and physical examination findings</measure>
    <time_frame>Day 1 through Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Oritavancin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-Dose IV Oritavancin Diphosphate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single-Dose IV Oritavancin Diphosphate</intervention_name>
    <description>Oritavancin will be administered as a single IV infusion. The infusion will last approximately 3 hours.</description>
    <arm_group_label>Oritavancin</arm_group_label>
    <other_name>Oritavancin Diphosphate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provides written informed consent before study initiation.

          -  Healthy male or female adult between 18 and 45 years of age, inclusive.

          -  Body mass index (BMI) between 18 and 32 kg/m2, inclusive.

          -  Nonsmoker for a 6 month period before Screening.

          -  In good health based upon results of medical history, physical examination, no
             clinically significant 12-lead ECG results, and laboratory test results.

          -  Agrees to avoid all medications (other than the study drugs) that may inhibit or
             induce hepatic microsomal enzymes during the study period, including prescription and
             nonprescription medications, vitamins, herbal supplements (including energy drinks),
             and nutraceuticals.

          -  Female subject is surgically sterile, postmenopausal, or, if of childbearing
             potential, agrees to use an acceptable nonhormonal method of contraception during all
             study phases.

          -  Agree to abstain from alcohol, caffeine-, and xanthine-containing products, all kind
             of energy drinks and the consumption of grapefruit juice and orange juice from 48
             hours before study drug administration until completion of the follow-up visit.

        Exclusion Criteria:

          -  Has acute or chronic respiratory disease.

          -  The use of nonprescription drugs during the 30 day period before screening.

          -  The use of any prescription drugs during the 3 month period before.

          -  Childbearing potential, a positive test result for urine or serum, human chorionic
             gonadotropin (hCG) at Screening.

          -  Positive serology result for hepatitis B surface antigen, hepatitis C virus antibody,
             or has known hepatitis B or C infection at screening.

          -  Positive serology result for human immunodeficiency virus (HIV) or has known immune
             deficiency disease at Screening.

          -  Requires anticoagulant monitoring with an activated partial thromboplastin time.

          -  Has an elevated international normalized ratio &gt;1.3.

          -  Surgical or medical condition that could interfere with the administration of the
             study drug.

          -  Any condition that may affect drug absorption.

          -  Has a known intolerance to benzodiazepines, the active and/or inactive ingredients in
             caffeine, warfarin, vitamin K, omeprazole, or dextromethorphan.

          -  The use of any nicotine containing substance or nicotine replacement devices within 6
             months before Screening.

          -  Has received an immunization during the 2 week period before screening.

          -  Has hemorrhagic tendencies or blood dyscrasias.

          -  Has poor venous access as determined by the investigator.

          -  Reports regular alcohol intake exceeding 1 drink/day within 1 month before screening.

          -  A poor metabolizer (based on medical history, if known) of CYP2D6, CYP2C9, or CYP2C19.

          -  Has participated in other clinical research studies involving the evaluation of other
             investigational drugs or devices within 30 days before enrollment.

          -  Excluded for any of the previous criteria may not be rescreened for participation at
             any time.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Sanabria, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spaulding Clinical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spaulding Clinical</name>
      <address>
        <city>West Bend</city>
        <state>Wisconsin</state>
        <zip>53095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2013</study_first_submitted>
  <study_first_submitted_qc>February 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2013</study_first_posted>
  <last_update_submitted>April 16, 2013</last_update_submitted>
  <last_update_submitted_qc>April 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oritavancin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

